MGA's ACSL BioMed software speeds drug development.
FDA, Pharmacia Upjohn are Among Organizations Turning to MGA's
Simulation Software to Bring Therapies to Patients Faster
Continuing to bring its proven expertise in simulation software into new markets, MGA Software, Inc. announced today the availability of ACSL BioMed, the first commercially available software for simulating clinical drug trials. With development costs for new drugs averaging $400 million over an 8-12 year period, a growing number of organizations including the FDA and Pharmacia Upjohn are using ACSL BioMed to improve their drug development process by reducing the number of failed trials, reducing costs and time to market.
Industries such as aerospace and automotive engineering have adopted and significantly benefited from simulation technology. Simulation software has enabled users in these industries to remain competitive by bringing better quality products to market faster, while decreasing development costs. Facing similar pressures, the biomedical industry is adopting simulation technology in order to speed the availability of new drugs and therapies. The industry is transitioning to a group of both large companies and small, focused startups where competition for investment and revenues for cancer, AIDS, and other drug therapies has increased. Trial designers in both large and small drug companies are adopting simulation software to give them an edge in cost reduction and time to market.
"As the principal pioneer in the development of simulation technology for over 20 years, MGA Software has consistently helped users streamline their development processes," said Michael Gauthier, president of MGA Software. "With the announcement of ACSL BioMed, our goal is to meet the needs of leading pharmaceutical companies, such as Pharmacia Upjohn, to improve their methodology and boost the likelihood of a successful trial. We are committed to helping these companies meet the needs of an increasingly demanding market."
For clinical trials ranging from a single patient to thousands of patients, ACSL BioMed will enable researchers to design, pre-test and modify study parameters before conducting actual live trials. Based on MGA's powerful simulation language ACSL (Advanced Continuous Simulation Language), ACSL BioMed lets researchers better understand the complex relationships between variables such as study design, dosing schemes, sampling approach and biological models. In addition, Monte Carlo analysis can be performed on the simulated data, including calculation of the study's power and survival statistics. BioMed also contains an interface to S-Plus and SAS, enabling clinicians to generate charts and graphs of the data using their existing analytical tools.
ACSL BioMed is the result of a collaboration between MGA Software and Dr. Mark Sale of Georgetown University Medical Center, where the product has been used to simulate several confidential trial designs with remarkable success.
Pricing and Availability
ACSL BioMed is currently available for customers with PC systems for $20,000. In addition, MGA's customers have access to the Company's superior consulting and technical support services. For help with specific modelling questions, customers can call 1-800-647- ACSL, email "firstname.lastname@example.org" for on-line help, or correspond with other ACSL users at "email@example.com". The Company also provides ACSL workshops on a regular basis.
MGA Software, founded in 1975, developed the first commercially successful language for modelling the dynamics of continuous systems -- ACSL (Advanced Continuous Simulation Language). Based on the Society for Computer Simulation's CSSL standard, ACSL is widely regarded as the standard software environment for modelling dynamic systems in industries such as aerospace, automotive, chemical processing, power plant design, agricultural and pharmaceutical research. MGA provides a full spectrum of industry solutions that include simulation specification, data analysis, hardware-in-the-loop testing, visualization and animation. Today, the privately held company has over 3,500 licenses worldwide representing over 10,000 users.
ACSL BioMed is a trademark of MGA Software Inc.
CONTACT: Michael Gauthier Jeanne MacMillan
MGA Software Inc. Sterling Hager,Inc.
|Printer friendly Cite/link Email Feedback|
|Date:||Feb 18, 1997|
|Previous Article:||Cheyenne Division of Computer Associates Adds New Tape Drive Monitoring Tool to Its Storage Management Solution Suite.|
|Next Article:||Belco Systems Technologies signs letter of intent.|